Souhaitez-vous accéder aux communiqués récents ?

MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd....

Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive...

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences   Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL® Findings support...

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic...

MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced...

EscharEx® Phase III VALUE trial advancing as planned Expanded NexoBrid® manufacturing facility operational; regulatory approvals expected in 2026 $17 million revenue in 2025; $54 million in...

Curtain Raiser for Q4 Earnings

MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair,...

MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference Interim assessment and enrollment completion for the EscharEx® VALUE Phase III trial in...

MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data show NexoBrid® removes...